Bladder Wall Thickness in Symptomatic Urinary Stress Incontinence and Its Correlation with Urodynamics Results

Not yet recruiting

• Conditions: Urinary Incontinence , Stress; Incontinence

• Registration Number: NCT06740058
• Lead Sponsor: IRCCS San Raffaele

Brief Summary

This clinical study aims to assess the utility of ultrasonographic bladder wall thickness (BWT) measurement in patients suffering from symptomatic stress urinary incontinence (SUI). SUI is a condition characterized by involuntary leakage of urine during activities that increase intra-abdominal pressure and represents a very frequent disorder impacting women's quality of life. To diagnose SUI more accurately and especially before surgical treatment, patients undergo invasive urodynamic examination. This examination allows us to objectify the presence of any bladder dysfunction and, in particular, to evaluate the presence of detrusor overactivity. Detrusor overactivity is defined as any occurrence of detrusor contraction(s) during filing cystometry. These contractions, which may be spontaneous or provoked, produce a waveform on the cystogram, of variable duration and amplitude and may cause or not urgency symptoms. In absence of any urodynamic detrusor overactivity, the patient may be diagnosed with pure SUI. This is essential to assess before surgical treatment to avoid worsening of symptoms and to decide whether to treat the patient with concomitant pharmacological treatment. On the contrary, ultrasonography offers a non-invasive and accessible approach to evaluate bladder function. This study will involve a cohort of patients with SUI, who will undergo ultrasonographic assessment of BWT and preoperative urodynamic assessment. The objective is to determine whether BWT correlates with the urodynamics results and whether it can predict the presence or absence of detrusor overactivity and confirm the pure stress urinary incontinence

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-12
• Study First Submitted: 2024-12-13
• Study First Submitted QC: 2024-12-17
• Last Update Submitted: 2024-12-17
• Study First Posted: 2024-12-18
• Last Update Posted: 2024-12-18
• Study Start: 2025-01
• Primary Completion: 2026-02
• Study Completion: 2026-02

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

1. Participant is willing and able to give informed consent for participation in the study.
2. Women aged > 18 y.o.
3. Women symptomatic for pure or predominant stress incontinence attending the urogynecology outpatient clinic at our institution.
4. Patients undergoing urogynecological standard evaluation for their symptoms, including outpatient gynecological visit and a transvaginal ultrasound.
5. Patients undergoing invasive urodynamic examination for objective assessment of their symptoms or in preparation for possible anti-incontinence surgery.

Read More

Exclusion Criteria

1. Patients with pure or predominant OAB symptomatology
2. Current use of antimuscarinic agents or beta3-agonists (for example Mirabegron)
3. Presence of urological or gynecological cancer.
4. Patients with previous anti-incontinence surgery.
5. Patients with pelvic organ prolapse > II stage.
6. Patients with chronic bladder retention.
7. Patients with neurological diseases that may affect bladder function and urodynamic results.
8. Participants unwilling or unable to give informed consent for participation in the study.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bladder wall thickness in millimeters (mm) in two different bladder points (dome and trigone) in patients with or without detrusor overactivity at urodynamic assessment	From enrollment to the urodynamic examination that will be performed with 6 months from baseline visit